Celgene Corp (CELG.OQ)
148.79USD
4:00pm EDT
$1.93 (+1.31%)
$146.86
$148.18
$149.91
$147.27
754,405
896,245
$149.91
$66.89
About
Overall
| Beta: | 0.80 |
| Market Cap (Mil.): | $60,400.00 |
| Shares Outstanding (Mil.): | 411.28 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CELG.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 40.97 | 47.13 | 37.76 |
| EPS (TTM): | 3.58 | -- | -- |
| ROI: | 16.58 | -2.58 | 18.76 |
| ROE: | 27.28 | -2.66 | 19.59 |
Celgene raises full-year outlook on strong cancer drug sales
- Biotechnology firm Celgene Corp raised its full-year earnings forecast for the second time in three months after it reported a quarterly profit above analysts' estimates, as its cancer drugs, Revlimid and Abraxane, continued to post strong sales growth.
Celgene profit tops estimates on strong cancer drug sales
- Biotechnology firm Celgene Corp reported a quarterly profit above analysts' estimates as demand for its cancer drugs, Revlimid and Abraxane, remained strong, and the company raised its full-year earnings forecast for the second time.
Celgene profit tops estimates on strong cancer drug sales
July 25 - Biotechnology firm Celgene Corp reported a quarterly profit above analysts' estimates as demand for its cancer drugs, Revlimid and Abraxane, remained strong, and the company raised its full-year earnings forecast for the second time.
Celgene to stop blood cancer trial due to high death rates
- Celgene Corp said it will stop a late-stage trial of its blood cancer drug, Revlimid, after it observed a higher number of deaths in elderly leukemia patients taking the drug compared with those on another treatment.
UPDATE 2-Celgene to stop blood cancer trial due to high death rates
* Shares down 2.7 pct (Adds analyst comments, company comments, updates share price)
CORRECTED-Celgene to stop blood cancer trial due to higher death rates
(Corrects paragraph 1 to say the drug was compared to another drug and not a placebo)
Market for Celgene blood cancer drug seen growing after trial
- Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in newly diagnosed blood cancer patients, potentially opening up the path for a wider use of the drug.
UPDATE 2-Market for Celgene blood cancer drug seen growing after trial
* Data can help Revlimid get approved for wider group of patients
Celgene's Revlimid improves survival in blood cancer patients
July 11 - Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in blood cancer patients.
UK cost agency says 'no' to Celgene bone marrow drug
LONDON - Celgene's drug Revlimid is not worth using on Britain's state health service because of uncertainty over whether it can extend the lives of patients with serious bone marrow disorders, the country's cost agency said on Thursday.
Competitors
| Price | Change | |
|---|---|---|
| Amgen, Inc. (AMGN.OQ) | $109.45 | +1.16 |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| Biogen Idec Inc (BIIB.OQ) | $220.22 | +2.09 |
| Bristol Myers Squibb Co. (BMY.N) | $43.99 | +0.75 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
| Eisai Co., Ltd (4523.T) | ¥4,165 | +20.00 |
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Streetwise Reports
|
$104.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
|
Provider: TheStreet.com Ratings
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

